MX2011011754A - Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b. - Google Patents

Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b.

Info

Publication number
MX2011011754A
MX2011011754A MX2011011754A MX2011011754A MX2011011754A MX 2011011754 A MX2011011754 A MX 2011011754A MX 2011011754 A MX2011011754 A MX 2011011754A MX 2011011754 A MX2011011754 A MX 2011011754A MX 2011011754 A MX2011011754 A MX 2011011754A
Authority
MX
Mexico
Prior art keywords
antibodies
compositions
methods
complement protein
protein
Prior art date
Application number
MX2011011754A
Other languages
English (en)
Spanish (es)
Inventor
Michael Roguska
Ingo Klagge
Braydon Charles Guild
Igor Splawski
Kehao Zhao
Yong-In Kim
Bijan Etemad-Gilbertson
Alexandra Kraus
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2011011754A publication Critical patent/MX2011011754A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2011011754A 2009-05-06 2010-05-05 Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b. MX2011011754A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17586009P 2009-05-06 2009-05-06
PCT/EP2010/056129 WO2010136311A2 (en) 2009-05-06 2010-05-05 Compositions and methods for antibodies targeting complement protein c3b

Publications (1)

Publication Number Publication Date
MX2011011754A true MX2011011754A (es) 2011-11-29

Family

ID=43063291

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011754A MX2011011754A (es) 2009-05-06 2010-05-05 Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b.

Country Status (22)

Country Link
US (1) US20100291106A1 (enExample)
EP (1) EP2427491A2 (enExample)
JP (1) JP2012525829A (enExample)
KR (1) KR20120088551A (enExample)
CN (1) CN102459334A (enExample)
AR (1) AR076655A1 (enExample)
AU (1) AU2010252156A1 (enExample)
CA (1) CA2760757A1 (enExample)
CL (1) CL2011002756A1 (enExample)
CO (1) CO6440515A2 (enExample)
EA (1) EA201101593A1 (enExample)
EC (1) ECSP11011445A (enExample)
IL (1) IL216061A0 (enExample)
MA (1) MA33402B1 (enExample)
MX (1) MX2011011754A (enExample)
PE (1) PE20120899A1 (enExample)
SG (1) SG175432A1 (enExample)
TN (1) TN2011000528A1 (enExample)
TW (1) TW201043638A (enExample)
UY (1) UY32612A (enExample)
WO (1) WO2010136311A2 (enExample)
ZA (1) ZA201107551B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512738B2 (en) 2004-04-30 2013-08-20 Allergan, Inc. Biodegradable intravitreal tyrosine kinase implants
PT2044111E (pt) 2006-06-21 2014-11-12 Univ Colorado Regents Abordagem seletiva do fator h do complemento para o tratamento de doenças
RS20120461A1 (sr) 2009-07-02 2013-06-28 Musc Foundation For Research Development Metode za stimulaciju regeneracije jetre
EP2496259B1 (en) 2009-11-05 2017-02-22 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria
JP5986990B2 (ja) 2010-05-14 2016-09-06 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレート 改善された補体レセプター２（ｃｒ２）ターゲティング基
MX2012014975A (es) 2010-06-22 2013-03-12 Univ Colorado Regents Anticuerpos al fragmento c3d de componente 3 de complemento.
WO2012075023A2 (en) * 2010-11-29 2012-06-07 Novelmed Therapeutics, Inc. Neoantibodies for diagnosing tissue injury
CN104220453B (zh) * 2012-04-03 2018-03-09 诺沃姆德治疗公司 人源化的嵌合抗因子c3抗体及其用途
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
WO2014066744A2 (en) 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
PL2914291T3 (pl) 2012-11-02 2022-10-03 Bioverativ Usa Inc. Przeciwciała anty-C1s dopełniacza i ich zastosowania
US9657111B2 (en) 2012-11-29 2017-05-23 Bayer Healthcare Llc Humanized monoclonal antibodies against activated protein C and uses thereof
EP3473272A1 (en) 2013-03-29 2019-04-24 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
SI3011345T1 (sl) 2013-08-07 2017-12-29 Alexion Pharmaceuticals, Inc. Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus)
CA2926812A1 (en) * 2013-10-07 2015-04-16 Massachusetts Eye And Ear Infirmary Methods of preventing or reducing photoreceptor cell death
WO2015099838A2 (en) 2013-12-24 2015-07-02 Novelmed Therapeutics, Inc. Compositions and methods of treating ocular diseases
KR20160126054A (ko) 2014-02-27 2016-11-01 알러간, 인코포레이티드 보체 인자 Bb 항체
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
EP4652926A3 (en) 2016-10-12 2026-03-18 Bioverativ USA Inc. Anti-c1s antibodies and methods of use thereof
EP3526248A4 (en) 2016-10-17 2020-07-08 Musc Foundation for Research Development COMPOSITIONS AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DAMAGE
KR20200138290A (ko) 2018-04-03 2020-12-09 엔지엠 바이오파마슈티컬스, 아이엔씨. C3-결합제 및 이의 사용 방법
EP4257602A3 (en) 2018-06-11 2023-12-27 Aarhus Universitet Single domain antibodies for complement regulation
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
EP4308609A4 (en) * 2021-03-19 2025-06-04 Elpis Biopharmaceuticals Antibodies specific to sialic acid-binding ig-like lectin 15 and uses thereof
WO2024108529A1 (en) * 2022-11-25 2024-05-30 Linno Pharmaceuticals Inc. Properdin binding protein and use thereof
PE20250390A1 (es) 2021-12-22 2025-02-11 Boehringer Ingelheim Int Anticuerpos anti-c3 y fragmentos de union al antigeno de estos y sus usos para tratar enfermedades oftalmicas u oculares
KR20230105972A (ko) * 2022-01-05 2023-07-12 주식회사 카나프테라퓨틱스 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
CN114874329A (zh) * 2022-05-19 2022-08-09 江苏大学 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用
US20240228652A9 (en) * 2022-09-20 2024-07-11 Visterra, Inc. Treatment of complement mediated diseases and disorders with c3b antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE452065B (sv) * 1986-04-11 1987-11-09 Ulf R Nilsson Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DK2026073T3 (en) * 2000-04-29 2016-07-25 Univ Iowa Res Found Diagnosis and treatment of macular degeneration-related disorders
US7838165B2 (en) * 2004-07-02 2010-11-23 Kabushiki Kaisha Toshiba Carbon fiber synthesizing catalyst and method of making thereof
WO2006012621A2 (en) * 2004-07-23 2006-02-02 University Of Virginia Patent Foundation Compositions and methods for regulating the alternative pathway of complement
CA2588892A1 (en) * 2004-12-02 2006-06-08 Dormantis Limited Anti-il-1r1 single domain antibodies and therapeutic uses
PL2860192T3 (pl) * 2005-10-12 2018-03-30 Morphosys Ag Wytwarzanie i profilowanie w pełni ludzkich, uzyskanych z HuCAL GOLD terapeutycznych przeciwciał swoistych wobec ludzkiego CD38
GB0613209D0 (en) * 2006-07-03 2006-08-09 Ucb Sa Methods
US8192742B2 (en) * 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
KR101572700B1 (ko) * 2007-06-07 2015-11-30 제넨테크, 인크. 보체-관련 장애의 예방 및 치료를 위한 Ｃ３ｂ 항체 및 방법
AR069130A1 (es) * 2007-11-02 2009-12-30 Novartis Ag Moleculas de enlace de la opsonina principal del complemento (c3b) y metodos para modular el componente de complemento

Also Published As

Publication number Publication date
WO2010136311A2 (en) 2010-12-02
EP2427491A2 (en) 2012-03-14
JP2012525829A (ja) 2012-10-25
AU2010252156A1 (en) 2011-11-10
MA33402B1 (fr) 2012-07-03
TN2011000528A1 (en) 2013-05-24
US20100291106A1 (en) 2010-11-18
CL2011002756A1 (es) 2012-03-23
KR20120088551A (ko) 2012-08-08
AR076655A1 (es) 2011-06-29
EA201101593A1 (ru) 2012-06-29
ZA201107551B (en) 2012-07-25
WO2010136311A3 (en) 2011-05-26
CA2760757A1 (en) 2010-12-02
CO6440515A2 (es) 2012-05-15
UY32612A (es) 2010-12-31
SG175432A1 (en) 2011-12-29
TW201043638A (en) 2010-12-16
IL216061A0 (en) 2012-01-31
ECSP11011445A (es) 2012-01-31
CN102459334A (zh) 2012-05-16
PE20120899A1 (es) 2012-08-03

Similar Documents

Publication Publication Date Title
AR076655A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
PH12013502205A1 (en) Antibodies to il-6 and their uses
CO7250445A2 (es) Proteínas de unión a antígeno st2
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
CR20120210A (es) Proteínas de enlace al antigeno il-23 humanas
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
EA201291067A1 (ru) Гуманизированные антигенсвязывающие белки к миостатину
EA201491214A1 (ru) Композиции и способы применения антител, нацеленных на фактор p
MX2018007630A (es) Anticuerpos contra la metaloproteinasa de matriz 9.
MX382826B (es) Anticuerpos dkk1 y metodos de uso.
UY32341A (es) Proteínas de unión antígeno novedosas
EA201291065A1 (ru) Антитела против vla-4
EA201491575A1 (ru) Антитела к матриксной металлопротеиназе 9
JO3437B1 (ar) أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
EA201590918A1 (ru) Антитела к bmp-6
EA201290977A1 (ru) Гуманизированные антитела к il-25
EA200900991A1 (ru) Новые антитела против igf-1r
AR118080A2 (es) Proteínas de unión a antígeno dirigidas contra el receptor
TH148296A (th) แอนติบอดีต้านเมทริกซ์เมทัลโลโปรตีเนส 9 (Antibodies to matrix metalloproteinase 9)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal